TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities:~* Follicular lymphoma grade 1 and 2~* Immunocytoma and lymphoplasmocytic lymphoma~* Marginal zone lymphoma, nodal and generalised~* Mantle cell lymphoma~* lymphocytic lymphoma (CLL without leucaemic characteristics)~* non-specified/classified lymphomas of low malignancy~* Recurrent disease (remission duration minimum 3 months), independent of type or quantity of prior therapies, except of Rituximab containing regimens, or if remission duration is \> 1 year after Rituximab containing regimen, or refractory to prior therapy (progression under therapy or during 3 months after completion), except refractory disease to purin analogs or Bendamustine~* Need for therapy, except mantle cell lymphomas~* Stadium II (bulky disease, 7.5 cm), II or IV~* Written informed consent~* Performance status WHO 0-2~* Histology not older than 6 months~Exclusion Criteria:~* Patients not establishing all above mentioned prerequisites~* Option of a primary, potentially curative radiation therapy~* Patients refractory to Rituximab containing regimens~* Comorbidities excluding a study conform therapy:~heart attack during the last 6 months severe, medicinal not adjustable hypertonia severe functional defects of the heart (NYHA III or IV) lung (WHO grade III or IV) liver or kidney (creatinine \> 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma~* Active auto immunohemolytic anemia (AIHA)~* HIV positive patients~* Active hepatitis infection~* Severe psychiatric diseases~* No compliance or non-compliance to be expected~* Pregnant or breast feeding women~* Anamnestic malignancies or secondary malignancies, not proven~* Cured/curable by surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine plus Rituximab (Type: EXPERIMENTAL): Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
- Fludarabine plus Rituximab (Type: ACTIVE_COMPARATOR): Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age 21 to 65 years inclusive~2. Diagnosis of obstructive sleep apnea (OSA) per International Classification of Sleep Disorders (ICSD-3)~3. BMI 18 to \<40 kg/m2~4. Willing and able to provide written informed consent~Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating~2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness~3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) criteria~4. History or presence of any unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy and/or safety assessments per the judgment of the investigator~5. History of bariatric surgery within the past year or a history of any gastric bypass procedure~6. Presence or history of significant cardiovascular disease~7. Unable to washout or refrain from taking any over-the-counter (OTC) or prescription medications that could affect sleep-wake function

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Once daily dosing
- JZP-110 (Type: ACTIVE_COMPARATOR): 150 mg/day for first 3 days and 300 mg/day for next 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effect of E-OA-07 on Acute Pain Response in Subjects Suffering From Knee OA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory adults of either sex aged 40 to 60 years.~* Subjects with moderate OA of the knee, which can be clinically, categorized as ARA functional Class II and III with radiological confirmation of Kellgren Lawrence Grade II and III. (incase of bilateral OA, the knee with the more severe symptoms will be defined as index joint)~* Subjects with OA in a flare state at the baseline defined by one of following category of flare:~In subjects who have been receiving non steroidal anti-inflammatory drugs (NSAIDs) or analgesic therapy for their OA, flare will be defined as having at least two of the following three criteria while comparing screening to baseline:~1. Subject's assessment of arthritis pain VAS walking on a flat surface at baseline of ≥ 40 mm;~2. Increase of ≥ 1 grade in the patients global assessment of arthritis;~3. Increase of ≥ 1 grade in the physician's global assessment of arthritis;~In subjects who are not receiving NSAID or analgesic therapy , an OA flare state will be defined as having at least two of the following three criteria~1. Subject's assessment of arthritis pain VAS walking on a flat surface at baseline of ≥ 40 mm~2. Patient's global assessment of arthritis of ''poor''; very poor~3. Physician's global assessment of arthritis of ''poor''; very poor~Exclusion Criteria:~* Subjects with any form of arthritis other than osteoarthritis.~* Administration of intra-articular or oral steroids in the past 3 month or intra articular hyaluronic acid in the last 9 months or parenteral use of NSAIDs~* History of major chronic hepatic, cardiovascular, neurological or immunosuppressive conditions or the presence of any infections~* Subjects with localized trauma to the lower limb~* Had received oral, intramuscular, or intra-articular corticosteroids within 8 weeks, or intra-articular hyaluronic acid in the index joint within 6 months of study drug administration;~* Subjects on nutritional supplement or herbal product since last one month~* Subjects otherwise judged by the investigator to be inappropriate for inclusion in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- E-OA-07 (Lanconone) (Type: EXPERIMENTAL): 500 mg two capsules to be taken stat at the site
- Ibuprofen (Type: ACTIVE_COMPARATOR): 200 mg two capsule to be taken stat at the site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of screening visit~* Diagnosis of Crohn's disease (CD) with a minimum duration of CD of at least 3 months~* Has draining perianal fistulae as a complication of CD, confirmed by magnetic resonance imaging (MRI) at screening~* Previously demonstrated an inadequate clinical response, loss of response to, or intolerance of at least 1 of the following agents (depending on current country treatment recommendations/guidelines):~  * Antibiotics AND/OR~ * Immunomodulators AND/OR~ * Tumor necrosis factor α (TNFα) Antagonist~* Is willing and able to undergo MRI per protocol requirements~* Is willing and able to undergo flexible sigmoidoscopy per protocol requirements~Key Exclusion Criteria:~* Presence of current rectovaginal anovaginal or enterovesicular fistulae~* Presence of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon~* History of total proctocolectomy, total colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study~* Use of any prohibited concomitant medications as described in the study protocol~* Active tuberculosis (TB) or history of latent TB that has not been treated~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
- Filgotinib 100 mg (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
- Placebo (Type: EXPERIMENTAL): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abatacept Versus Adalimumab Head-to-Head

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria~* Methotrexate failure~* Naive to RA biologics~* ≤5 years duration of disease~* Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2~* Willingness to self-inject subcutaneous (SC) drug~Exclusion Criteria:~* Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents~* History of active or chronic hepatitis~* Cancer in the last 5 years~* History of severe chronic or recurrent bacterial or viral infections~* Risk of tuberculosis~* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: ACTIVE_COMPARATOR): None
- Adalimumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with intestinal colonization by Klebsiella pneumoniae, defined as the presence of a positive rectal swab culture at least 7 days prior to initiation of therapy; and patients considered at risk of developing an invasive infection by Klebsiella pneumoniae:~* Surgery in two weeks~* Transplant in two weeks~* Require medical intervention or has a clinical situation that may predispose to the development of a serious infection (chemotherapy, immunosuppression or neutropenia)~* Recurrent or severe infections~* Institution admission~* Fragile patients at high risk of readmission.~Exclusion Criteria:~* The presence of an active infection for Klebsiella Pneumoniae.~* Concomitant use of systemic antibiotics in the 14 days before the start of decolonization therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Received therapy desconolizacion against Klebsiella pneumoniae (Type: None): None
- Patients who do not receive the therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* type 2 diabetes mellitus, with stable metformin treatment for \>=3 months;~* stable weight +/-10% for \>=3 months before screening.~Exclusion Criteria:~* type 1 diabetes mellitus;~* treatment with any anti-hyperglycemic medication other than metformin monotherapy during last 3 months;~* use of weight-lowering medications in the last 3 months;~* uncontrolled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For LOV111818/OM6X - Subjects were included in the study if they had met all relevant inclusion/exclusion criteria prior to and throughout the double-blind Study LOV111858/OM6 and completed Study LOV111858/OM6 to Week 8.~FYI - entry criteria for LOV111818/OM6 (double-blind study)~Inclusion Criteria:~* Men and women ages 18-79 years, inclusive~* Current therapy with a statin drug~* Triglyceride levels between 200 and 499 mg/dL~* Normally active and in good health on the basis of medical history, brief physical examination, electrocardiogram, and routine laboratory tests~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Sensitivity to statin drugs or omega-3 fatty acids~* Lipoprotein lipase impairment or apo C-2 deficiency or type III hyperlipidemia~* Unexplained muscle pain or weakness~* History of pancreatitis~* Recent history of certain heart, kidney, liver, lung, or gastrointestinal diseases, or cancer (except non-melanoma skin cancer)~* Poorly controlled diabetes, or receiving insulin therapy~* Pregnant or lactating females. Women of childbearing potential who are not using a medically approved method of contraception.~* Use of certain types of hormones, anticonvulsant drugs, immunologic drugs, antibiotic, antifungal and antiviral drugs, and cardiac drugs~* Use of warfarin (Coumadin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin + Lovaza® (Non-switchers) (Type: EXPERIMENTAL): Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers
- Simvastatin + Lovaza® (Switchers) (Type: EXPERIMENTAL): Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Has undergone abdominoplasty with no additional collateral procedures.~* Experiences a pain intensity rating of moderate to severe acute pain.~* Able to provide written informed consent before any study procedure.~Exclusion Criteria:~* ASA Physical Status Classification System classification of P3 or worse.~* Has surgical or post-surgical complications.~* Has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs.~* Has previously participated in another TRV130 clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Treatment 1 Oliceridine (Type: EXPERIMENTAL): None
- Treatment 2 Oliceridine (Type: EXPERIMENTAL): None
- Treatment 3 Oliceridine (Type: EXPERIMENTAL): None
- Treatment 4 Placebo (Type: PLACEBO_COMPARATOR): None
- Treatment 5 Morphine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM who are not receiving treatment with any anti-hyperglycemic agents (AHAs) for at least 12 weeks, or who are receiving treatment with a stable dose and regimen of metformin monotherapy for at least 12 weeks and have a hemoglobin A1c (HbA1c) in the range of \>=7% to \<=10%~Exclusion Criteria:~* History of Type 1, brittle diabetes or secondary forms of diabetes~* History of 1 or more severe hypoglycemic episodes~* History of diabetic complications considered to be clinically significant by the Investigator~* History of or current illness considered to be clinically significant by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: no Intervention (Type: NO_INTERVENTION): In Part 1 of the study, patients will not receive any study drug.
- Part 2: canagliflozin (Type: EXPERIMENTAL): In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with a liver transplant performed in the previous year and for whom the conversion from Prograf® to Advagraf® was decided by the physician.~Exclusion Criteria:~* Patient participating in an interventional clinical trial at the time of enrolment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1:early conversion from Prograf® to Advagraf® (Type: None): patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
- 2:late conversion from Prograf® to Advagraf® (Type: None): patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patient~* Patient diagnosed with Interstitial pneumonia associated with polymyositis/dermatomyositis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Dermatomyositis group (Type: None): patients with interstitial pneumonia associated with dermatomyositis
- 2: Polymyositis group (Type: None): patients with interstitial pneumonia associated with polymyositis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Different Doses of Vitamin D and T Regulatory Cells in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants with gestational age 28-33 weeks~Exclusion Criteria:~* Necrotizing enterocolitis~* Bowel perforation~* Chromosomal anomalies~* Inborn errors of metabolism~* Major congenital anomalies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Low dose (Type: EXPERIMENTAL): Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
- High dose (Type: EXPERIMENTAL): Subjects in this group receive 800 IU vitamin D daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete